News
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.
FEATURED STORIES
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Laurence F. Doud III, the former chief executive officer of Rochester Drug Co-Operative, Inc. (RDC), one of the 10 largest pharmaceutical distributors in the United States, ignored what U.S. prosecutors have called “serious red flags” surrounding the sale of opioid drugs.
Psychedelic-focused drug company Eleusis is merging with Silver Spike Acquisition Corp. II, a special purposes acquisition company, and heading to the Nasdaq with a combined enterprise value of $446 million.
As part of a company-wide workforce reduction, it will cut its employee headcount by at least 25% by the end of the year, and 50% of its senior management team are leaving the company.
World tennis superstar Novak Djokovic reportedly has an 80% stake in QuantBioRes that’s currently working on finding a treatment, not a vaccine, for COVID-19.
The funds will be used to advance the firm’s precision oncology research efforts and pipeline, particularly those involving the creation of alteration-specific therapies.
Dr. Anthony Fauci expects the FDA will authorize the Pfizer-BioNTech vaccine for children under the age of five in the next month.
ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.
Unilever announced Wednesday that it will not increase its bid over the recently proposed £50 billion (about $68 billion) to ensure that the acquisitions create value for its shareholders.
With more and more people applying for remote positions, how can you stand out among the massive stacks of applications?
Such a deep, data-driven approach is enabling precision medicine, in particular, which is expanding from oncology to autoimmune diseases and other conditions.